Product Center
Obtained Recognition as One of the First Offshore Innovation Centers for Enterprises in Taizhou
- Categories:Company news
- Author:
- Origin:
- Time of issue:2024-08-14
- Views:
(Summary description)Recently, the Science and Technology Bureau of Taizhou City announced the first batch of offshore innovation centers for enterprises, and Ab&B Bio-Tech Co., Ltd. (Ab&B Bio) wholly-owned subsidiary Yither Biotech (Shanghai) Co., Ltd. (Yither Bio) successfully obtained recognition.
Obtained Recognition as One of the First Offshore Innovation Centers for Enterprises in Taizhou
(Summary description)Recently, the Science and Technology Bureau of Taizhou City announced the first batch of offshore innovation centers for enterprises, and Ab&B Bio-Tech Co., Ltd. (Ab&B Bio) wholly-owned subsidiary Yither Biotech (Shanghai) Co., Ltd. (Yither Bio) successfully obtained recognition.
- Categories:Company news
- Author:
- Origin:
- Time of issue:2024-08-14 18:02
- Views:
Recently, the Science and Technology Bureau of Taizhou City announced the first batch of offshore innovation centers for enterprises, and Ab&B Bio-Tech Co., Ltd. (Ab&B Bio) wholly-owned subsidiary Yither Biotech (Shanghai) Co., Ltd. (Yither Bio) successfully obtained recognition.
Since its establishment, Yither Bio has jointly established a collaborative innovation model of "offshore research and development incubation, local transformation and application" with Ab&B Bio, leveraging advanced regional innovative resources to carry out key core technology research and development. As of now, two clinical approvals for Class I new drugs have been successfully jointly applied for and approved.
Next, the company will also actively promote the two-way linkage between local innovation and offshore innovation, strengthen the exchange, interaction and circulation of talents, cultivate a batch of scientific and technological innovation achievements, and continue to complete the implementation and application of innovation achievements, so as to help the high-quality development of the city's biomedical industry!
Relevant information
-
Phase I/II Clinical Trial of the Re engineered Respiratory Syncytial Virus Vaccine (CHO Cells)(Adjuvant)Officially LaunchedOn May 13, the launch meeting for the Phase I/II clinical trial of the recombinant respiratory syncytial virus vaccine (CHO cell-based) (adjuvant) independently developed by Ab&B Bio-Tech CO.,LTD.JS. (Ab&B Bio) was successfully held at the research site in Sichuan. - The mRNA technology platform has achieved another milestone, with global innovation efforts accelerating. 05-08
- Our innovative vaccine research team won the 20th "Jiangsu Youth May Fourth Medal Collective" award 04-27
- The Ab&B Bio Promotion Business Conference and 10th Anniversary Celebration were successfully held 04-25
- Steadily promoting national recruitment and supplementation standards, the first and only trivalent influenza virus subunit vaccine for the entire population helps global 2026 influenza prevention and control! 04-14
Got a project? Contact us today !
At Ab&B Bio, our mission is to care for life and protect health by developing globally innovative vaccines.
Contact
E-mail:haixin.zhang@yitherbiotech.com
Add:No. 32, Xinglin Road, Medical High-tech Zone, Taizhou City
Quick view
Follow us
